NCT00227240

Brief Summary

The purpose of this study is to investigate the incidences of adverse events for patients with plaque psoriasis treated with Enbrel under usual care settings.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
753

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2005

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2005

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
14 days until next milestone

First Posted

Study publicly available on registry

September 27, 2005

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2009

Completed
Last Updated

March 21, 2012

Status Verified

March 1, 2012

Enrollment Period

4.2 years

First QC Date

September 13, 2005

Last Update Submit

March 20, 2012

Conditions

Plaque Psoriasis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

primary care clinical and community sample

You may qualify if:

  • Proven diagnosis of Plaque Psoriasis

You may not qualify if:

  • Contraindications according to SmPC of Enbrel

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Pfizer Investigational Site

Munich, 81366, Germany

Location

Pfizer Investigational Site

München, 80337, Germany

Location

Related Links

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 27, 2005

Study Start

April 1, 2005

Primary Completion

June 1, 2009

Study Completion

June 1, 2009

Last Updated

March 21, 2012

Record last verified: 2012-03

Locations

DE(2)